Floreo's New Scientific Advisory Board Champions VR Therapy
Floreo, a trailblazer in virtual reality (VR) therapy for neurodivergent individuals, proudly announces the formation of its inaugural scientific advisory board. The board will consist of six distinguished leaders from the realms of behavioral health research, clinical practice, and healthcare delivery, enhancing Floreo's commitment to innovative therapies.
Purpose and Goals of the Advisory Board
Chaired by Dr. Paula Pompa-Craven, Chief Clinical Officer at Easterseals Southern California, the board aims to provide strategic direction for Floreo's ongoing research and clinical studies. Dr. Pompa-Craven brings a wealth of experience in the assessment and treatment of autism and developmental disabilities, greatly benefiting Floreo's mission.
Collaboration at its Core
As stated by Vijay Ravindran, CEO and founder of Floreo, "There is a real urgency and demand for effective, evidence-based interventions for individuals living with autism. We see a tremendous opportunity for collaboration across scientific, clinical, and technology communities." The board's insights will be pivotal in shaping Floreo's future developments.
Floreo's Innovative VR Therapy Lessons
Floreo's immersive VR lessons are designed for both clinical and educational settings to assist individuals with Autism Spectrum Disorder, ADHD, and other diagnoses in developing essential skills. This innovative approach enables learners to enhance social skills, emotional regulation, and daily living capabilities.
In a remarkable achievement for 2023, Floreo became the first VR technology for autism treatment to obtain the FDA's breakthrough device designation. This recognition underscores the potential impact of Floreo's solutions on the neurodiverse community.
Meet the Founding Members of the Board
The board includes several visionaries contributing to the ongoing evolution of VR therapy:
- Dr. Paula Pompa-Craven, Psy.D. - As the chief clinical officer at Easterseals Southern California, she oversees a vast network of services for individuals with disabilities and champions high standards in clinical assessment and support.
- Retired U.S. Army Major General Elder Granger, M.D. - A healthcare consultant with a distinguished military background, he previously led healthcare services for millions of Americans and supports Floreo’s commitment to high-quality care.
- Dr. Rhonda Moore, PhD - An Autistic cultural anthropologist, Dr. Moore's work focuses on the intersection of disability and lived experience, enriching Floreo's understanding of neurodiversity.
- Anna Moznavsky, M.A., BCBA - As the Senior Vice President of Clinical Operations and Quality at the Center for Social Dynamics, she leads initiatives that improve clinical outcomes and training for professionals.
- Marsha Stepensky, MS.Ed., BCBA - As Director of Therapy Content at Floreo, Marsha utilizes her extensive clinical background to develop effective VR lesson plans for diverse learners.
- Shirley Mak-Parisi - With years of experience in clinical research, she enhances evidence-based practices within Floreo, ensuring the delivery of safe and effective therapies.
Floreo's Vision for the Future
Floreo envisions a world where every neurodiverse individual can thrive. The company is dedicated to creating the first behavioral therapy metaverse—a safe virtual space where learners can hone skills for everyday situations. Through their innovative VR platform, Floreo aims to teach vital social, behavioral, and life skills to individuals with varying neurodiverse conditions.
Frequently Asked Questions
What is the purpose of Floreo's scientific advisory board?
The board aims to provide strategic direction for research, clinical study design, and validation of Floreo's VR-based learning tools.
Who chairs the scientific advisory board?
Dr. Paula Pompa-Craven, the Chief Clinical Officer of Easterseals Southern California, chairs the board.
What types of conditions does Floreo's VR therapy target?
Floreo's VR therapy is designed for individuals with Autism Spectrum Disorder, ADHD, anxiety, and other neurodiverse conditions.
What recognition has Floreo achieved for its technology?
In 2023, Floreo received the FDA's breakthrough device designation for its innovative VR technology aimed at autism treatment.
How can I learn more about Floreo?
For more information about Floreo and its initiatives, please visit their official website.
